Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLR1A | O95602 | 19/20 | 1.00 |
| ▸ | ECE1 | P42892 | 1/20 | 0.70 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17099668 | 0.92 | POLR1A (1.00) | POLR1A | |
| SCHEMBL17099655 | 0.91 | POLR1A (1.00) | POLR1A | |
| SCHEMBL25361484 | 0.90 | POLR1A (0.82) | POLR1AECE1MUS81KDM4EMEN1 | |
| SCHEMBL17117514 | 0.90 | POLR1A (1.00) | POLR1AECE1MUS81NPSR1 | |
| SCHEMBL17117509 | 0.90 | POLR1A (0.84) | POLR1AECE1MUS81 | |
| SCHEMBL26004009 | 0.90 | POLR1A (1.00) | POLR1AECE1MUS81KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL30527191 | 0.89 | POLR1A (0.81) | POLR1AECE1MUS81KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL29646593 | 0.89 | POLR1A (0.98) | POLR1AECE1MUS81KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL29646594 | 0.89 | POLR1A (0.98) | POLR1AECE1MUS81KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL25356073 | 0.89 | POLR1A (0.98) | POLR1AECE1MUS81KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515448-B1 | COMBINATORY TREATMENT STRATEGIES OF CANCER BASED ON RNA POLYMERASE I INHIBITION | UNIV JOHNS HOPKINS (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11001581-B2 | Compounds which inhibit RNA polymerase, compositions including such compounds, and their use | The Johns Hopkins University and Lieber Institute, Inc. (US) | 2021-05-11 | — | — | US | disclosed |
| US-11001581-B2 | Compounds which inhibit RNA polymerase, compositions including such compounds, and their use | The Johns Hopkins University and Lieber Institute, Inc. (US) | 2021-05-11 | — | — | US | disclosed |
| EP-3778600-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE, COMPOSITIONS INCLUDING SUCH COMPOUNDS, AND THEIR USE | The Johns Hopkins University (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778600-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE, COMPOSITIONS INCLUDING SUCH COMPOUNDS, AND THEIR USE | The Johns Hopkins University (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3119781-B1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE, COMPOSITIONS INCLUDING SUCH COMPOUNDS, AND THEIR USE | UNIV JOHNS HOPKINS (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3119781-B1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE, COMPOSITIONS INCLUDING SUCH COMPOUNDS, AND THEIR USE | UNIV JOHNS HOPKINS (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20190247397-A1 | COMBINATORY TREATMENT STRATEGIES OF CANCER BASED ON RNA POLYMERASE I INHIBITION | THE JOHNS HOPKINS UNIVERSITY | 2019-08-15 | — | — | US | disclosed |
| WO-2018057834-A1 | COMBINATORY TREATMENT STRATEGIES OF CANCER BASED ON RNA POLYMERASE I INHIBITION | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-03-29 | — | — | WO | disclosed |
| US-20170081322-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE, COMPOSITIONS INCLUDING SUCH COMPOUNDS, AND THEIR USE | THE JOHNS HOPKINS UNIVERSITY | 2017-03-23 | — | — | US | disclosed |
| US-20170081322-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE, COMPOSITIONS INCLUDING SUCH COMPOUNDS, AND THEIR USE | THE JOHNS HOPKINS UNIVERSITY | 2017-03-23 | — | — | US | disclosed |
| US-20170081322-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE, COMPOSITIONS INCLUDING SUCH COMPOUNDS, AND THEIR USE | THE JOHNS HOPKINS UNIVERSITY | 2017-03-23 | — | — | US | disclosed |
| EP-3119781-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE, COMPOSITIONS INCLUDING SUCH COMPOUNDS, AND THEIR USE | The Johns Hopkins University (US) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015143293-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE, COMPOSITIONS INCLUDING SUCH COMPOUNDS, AND THEIR USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015143293-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE, COMPOSITIONS INCLUDING SUCH COMPOUNDS, AND THEIR USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001581-B2 | Compounds which inhibit RNA polymerase, compositions including such compounds, and their use | POLR2H, MED25, POLR1A | POLR1A 3/4885ECE1 4231/4885MUS81 168/4885 |
| US-20190247397-A1 | COMBINATORY TREATMENT STRATEGIES OF CANCER BASED ON RNA POLYMERASE I INHIBITION | ACAT1, PARP1, POLRMT | POLR1A 7/4885ECE1 2998/4885MUS81 2784/4885 |
| US-20170081322-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE, COMPOSITIONS INCLUDING SUCH COMPOUNDS, AND THEIR USE | POLR2H, MED25, POLR1A | POLR1A 3/4885ECE1 4231/4885MUS81 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.